Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11677768 | 0.81 | POLB (0.74) | POLBKMT2APDE4APDE4BPDE4C | |
| SCHEMBL11378894 | 0.81 | POLB (1.00) | POLBKMT2APDE4APDE4BPDE4C | |
| SCHEMBL5584023 | 0.79 | POLB (0.71) | POLBKMT2APDE4APDE4BPDE4C | |
| SCHEMBL11847614 | 0.77 | POLB (0.68) | POLBKMT2APDE4APDE4BPDE4C | |
| SCHEMBL19404136 | 0.77 | POLB (0.68) | POLBKMT2APDE4APDE4BPDE4C | |
| SCHEMBL561241 | 0.77 | POLB (0.68) | POLBKMT2APDE4APDE4BPDE4C | |
| SCHEMBL11694927 | 0.77 | POLB (0.68) | POLBKMT2APDE4APDE4BPDE4C | |
| SCHEMBL13753309 | 0.76 | POLB (0.65) | POLBKMT2APDE4APDE4BPDE4C | |
| SCHEMBL9787811 | 0.76 | POLB (0.65) | POLBKMT2APDE4APDE4BPDE4C | |
| SCHEMBL11694716 | 0.76 | POLB (0.65) | POLBKMT2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9248117-B2 | Substituted N,N-dihaloamines as antimicrobials | NOVABAY PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2341777-B1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | NOVABAY PHARMACEUTICALS INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8722715-B2 | Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions | NovaBay Pharmaceuticals (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2629607-A2 | ANTIMICROBIAL POLYETHER AND POLYOL COMPOUNDS | NovaBay Pharmaceuticals, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012054521-A2 | ANTIMICROBIAL POLYETHER AND POLYOL COMPOUNDS | NOVABAY PHARMACEUTICLAS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20100137349-A1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137349-A1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | OXA1L, NISCH, ODC1 | POLB 1432/4885KMT2A 2188/4885PDE4A 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.